DBV Technologies (DBVT) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.

DBV submitted its BLA for VIASKIN Peanut in 4-to-7-year-olds. Existing cash of $165.7 million funds operations into third-quarter 2027.…

DBV Technologies NASDAQ: DBVT is preparing for a potential U.S. launch of its peanut allergy patch for children ages 4 to 7 while awaiting a decision on whether regulators will accept its biologics license application, e…

DBV Technologies is rated Speculative Strong Buy with a $42 per ADS fair value, despite recent sector- and company-specific share price declines. My revised DCF incorporates higher discount rates, regulatory delay probab…

Châtillon, France, November 2, 2026 DBV Technologies to Participate in Upcoming November Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the “Company”), a late-stag…

DBV Technologies S.A. (DBVT) Q3 2026 Earnings Call Transcript…

DBV Technologies NASDAQ: DBVT said it submitted a biologics license application, or BLA, to the U.S. Food and Drug Administration for its VIASKIN Peanut patch in children ages 4 to 7, while continuing preparations for a …

Châtillon, France, October 28, 2026 DBV Technologies Reports Third Quarter 2026 Financial Results and Business Update Submitted the Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in children aged…

Châtillon, France, October 27, 2026 DBV Technologies to Report Third Quarter 2026 Financial Results and Business Update on October 28, 2026 Company to host investor conference call and webcast at 5:00pm ET DBV Technologi…

DBV Technologies (NASDAQ: DBVT - Get Free Report) and Arrowhead Pharmaceuticals (NASDAQ: ARWR - Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based o…

DBV Technologies S.A. (NASDAQ: DBVT - Get Free Report) shares reached a new 52-week low during mid-day trading on Wednesday. The stock traded as low as $8.90 and last traded at $9.03, with a volume of 344,103 shares trad…

Shares of DBV Technologies S.A. (NASDAQ: DBVT - Get Free Report) hit a new 52-week low on Thursday. The company traded as low as $9.64 and last traded at $9.77, with a volume of 535276 shares changing hands. The stock ha…

DBV Technologies S.A. (NASDAQ: DBVT - Get Free Report) shares gapped down prior to trading on Thursday. The stock had previously closed at $11.76, but opened at $11.30. DBV Technologies shares last traded at $11.32, with…

Châtillon, France, September 29, 2026 DBV Technologies Announces Submission of Biologics License Ap p lication to U.S. FDA for the VIASKIN ® Peanut Patch in Children Aged 4-7 Years The BLA is supported by the results fro…

DBV Technologies (NASDAQ: DBVT - Get Free Report) and XTL Biopharmaceuticals (NASDAQ: XTLB - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesse…

Châtillon, France, September 3, 2026 DBV Technologies to Participate in Upcoming September Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the “Company”), a late-st…
Kept in their own lane. A press release is the company talking, not reporting.
No upcoming events in the feeds.

